Combined effect of 25-OH vitamin D plasma levels and genetic Vitamin D Receptor (NR 1I1) variants on fibrosis progression rate in HCV patients

Liver International

Volumn 32, Issue 4, 2012, Pages 635-643

  Baur, Katharina ^a   Mertens, Joachim C ^a   Schmitt, Johannes ^a   Iwata, Rika ^a   Stieger, Bruno ^a,b   Eloranta, Jyrki J ^a,b   Frei, Pascal ^a   Stickel, Felix ^c   Dill, Michael T ^d   Seifert, Burkhardt ^e   Bischoff Ferrari, Heike A ^b   von Eckardstein, Arnold ^a   Bochud, Pierre Yves ^f   Müllhaupt, Beat ^a   Geier, Andreas ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

Fibrosis progression; Hepatitis C; VDR bAt haplotype; Vitamin D; Vitamin D receptor polymorphisms

Indexed keywords

25 HYDROXYVITAMIN D; VITAMIN D RECEPTOR;

ADULT; AGED; ARTICLE; BLOOD LEVEL; DISEASE COURSE; DNA POLYMORPHISM; FEMALE; GENOTYPE; HAPLOTYPE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; RISK FACTOR;

CALCITRIOL; DISEASE PROGRESSION; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MULTIVARIATE ANALYSIS; RECEPTORS, CALCITRIOL; SWITZERLAND;

EID: 84858281844     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2011.02674.x     Document Type: Article

References (37)

1. Seeff LB, Hoofnagle JH. National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002. Hepatology 2002; 5(Suppl 1): S1-2.
2. Valdivielso JM, Fernandez E. Vitamin D receptor polymorphisms and diseases. Clin Chim Acta 2006; 371: 1-12.
3. Arteh J, Narra S, Nair S. Prevalence of vitamin D deficiency in chronic liver disease. Dig Dis Sci 2010; 55: 2624-8.
4. Geier A. Shedding new light on vitamin D and fatty liver disease. J Hepatol 2011; 55: 273-5.
5. Fisher L, Fisher A. Vitamin D and parathyroid hormone in outpatients with noncholestatic chronic liver disease. Clin Gastroenterol Hepatol 2007; 5: 513-20.
6. Tsuneoka K, Tameda Y, Takase K, Nakano T. Osteodystrophy in patients with chronic hepatitis and liver cirrhosis. J Gastroenterol 1996; 31: 669-78.
7. Petta S, Camma C, Scazzone C, et al. Low vitamin D serum level is related to severe fibrosis and low responsiveness to interferon-based therapy in genotype 1 chronic hepatitis C. Hepatology 2010; 51: 1158-67.
8. Lange CM, Bojunga J, Ramos-Lopez E, et al. Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J Hepatol 2011; 54: 887-93.
9. Terrier B, Carrat F, Geri G, et al. Low 25-OH vitamin D serum levels correlate with severe fibrosis in HIV-HCV co-infected patients with chronic hepatitis. J Hepatol 2011; 55: 756-61.
10. Targher G, Bertolini L, Scala L, et al. Associations between serum 25-hydroxyvitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17: 517-24.
11. Uitterlinden AG, Fang Y, Van Meurs JB, Pols HA, Van Leeuwen JP. Genetics and biology of vitamin D receptor polymorphisms. Gene 2004; 338: 143-56.
12. Wang TJ, Zhang F, Richards JB, et al. Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 2010; 376: 180-8.
13. Vogel A, Strassburg CP, Manns MP. Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 2002; 35: 126-31.
14. Sandgren ME, Bronnegard M, DeLuca HF. Tissue distribution of the 1, 25-dihydroxyvitamin D3 receptor in the male rat. Biochem Biophys Res Commun 1991; 181: 611-6.
15. Segura C, Alonso M, Fraga C, et al. Vitamin D receptor ontogenesis in rat liver. Histochem Cell Biol 1999; 112: 163-7.
16. Gascon-Barre M, Demers C, Mirshahi A, et al. The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 2003; 37: 1034-42.
17. Evans R. Nuclear receptors and liver disease - the Hyman Zimmerman state-of-the-art lecture. In: Annual meeting American association for the study of liver disease. Boston, MA; 2008. Available at (accessed 24 November 2011).
18. Prasad L, Spicher VM, Zwahlen M, et al. Cohort Profile: the Swiss Hepatitis C Cohort Study (SCCS). Int J Epidemiol 2007; 36: 731-7.
19. Deuffic-Burban S, Poynard T, Valleron AJ. Quantification of fibrosis progression in patients with chronic hepatitis C using a Markov model. J Viral Hepat 2002; 9: 114-22.
20. Bochud PY, Cai T, Overbeck K, et al. Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C. J Hepatol 2009; 51: 655-66.
21. Meier Y, Pauli-Magnus C, Zanger UM, et al. Interindividual variability of canalicular ATP-binding-cassette (ABC)-transporter expression in human liver. Hepatology 2006; 44: 62-74.
22. Iwata R, Stieger B, Mertens J, et al. A common polymorphism in the ABCB11 gene encoding for the bile salt export pump is associated with progression to cirrhosis in hepatitis C (HCV) infection. Swiss Med Wkly 2009; 139: 8S-8S.
23. Hou MF, Tien YC, Lin GT, et al. Association of vitamin D receptor gene polymorphism with sporadic breast cancer in Taiwanese patients. Breast Cancer Res Treat 2002; 74: 1-7.
24. Li C, Liu Z, Zhang Z, et al. Genetic variants of the vitamin D receptor gene alter risk of cutaneous melanoma. J Invest Dermatol 2007; 127: 276-80.
25. Hutchinson PE, Osborne JE, Lear JT, et al. Vitamin D receptor polymorphisms are associated with altered prognosis in patients with malignant melanoma. Clin Cancer Res 2000; 6: 498-504.
26. Taylor JA, Hirvonen A, Watson M, et al. Association of prostate cancer with vitamin D receptor gene polymorphism. Cancer Res 1996; 56: 4108-10.
27. Rodriguez S, Gaunt TR, Day IN. Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies. Am J Epidemiol 2009; 169: 505-14.
28. Lichtinghagen R, Bahr MJ, Wehmeier M, et al. Expression and coordinated regulation of matrix metalloproteinases in chronic hepatitis C and hepatitis C virus-induced liver cirrhosis. Clin Sci (Lond) 2003; 105: 373-82.
29. Reif S, Somech R, Brazovski E, et al. Matrix metalloproteinases 2 and 9 are markers of inflammation but not of the degree of fibrosis in chronic hepatitis C. Digestion 2005; 71: 124-30.
30. Timms PM, Mannan N, Hitman GA, et al. Circulating MMP9, vitamin D and variation in the TIMP-1 response with VDR genotype: mechanisms for inflammatory damage in chronic disorders? QJM 2002; 95: 787-96.
31. Bahar-Shany K, Ravid A, Koren R. Upregulation of MMP-9 production by TNFalpha in keratinocytes and its attenuation by vitamin D. J Cell Physiol 2010; 222: 729-37.
32. Hemmann S, Graf J, Roderfeld M, Roeb E. Expression of MMPs and TIMPs in liver fibrosis - a systematic review with special emphasis on anti-fibrotic strategies. J Hepatol 2007; 46: 955-75.
33. Rode A, Fourlanos S, Nicoll A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol Clin Biol 2010; 34: 618-20.
34. Crawford BA, Labio ED, Strasser SI, McCaughan GW. Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol 2006; 3: 689-99.
35. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38: 1449-57.
36. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97: 2614-8.
37. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology, 2005; 41: 257-64.